CoVid-19’s initial symptoms include fever, cough, shortness of breath, fatigue and loss of taste or smell. Moreover, the additional complications can affect the cardiovascular system, kidneys, liver and lungs.
One of the identified underlying dysfunctions that trigger shortness of breath and severe lung complications is hypercoagulability. In one study, patients who were admitted to Padova University Hospital in Italy for acute respiratory failure showed “markedly hypercoagulable thromboelastometry profiles.”
Clot formations throughout the body may be associated with other complications arising after the illness has resolved. It appears that the difference between people who have a mild or severe illness may be related to the body’s ability to reduce the hypercoagulability and the hyperimmune response that leads to a cytokine storm.
An antioxidant is a molecule that keeps other molecules from oxidizing. Glutathione is a powerful antioxidant that may play a significant role in the COVID-19 illness process.
There are three amino acids that line up to form a glutathione molecule. These are cystine, glycine and glutamate. Together they help use and recycle other antioxidants, such as vitamin C and CoQ10.
This means your body uses glutathione to increase the effectiveness of these antioxidants and it helps to recycle the molecules. Without glutathione, the antioxidant capacity is significantly reduced. This function may be what earned glutathione the nickname “master antioxidant.”
N-acetylcysteine (NAC) plays a role as a precursor to glutathione. Clinical evidence has also demonstrated the effects NAC has, independent of its role with glutathione, including a thrombolytic effect. It also improves oxidative stress and the inflammatory response.
In late March 2020, one medical student put this theory to the test when his mother, 48-year-old Josephine Bruzzese, was diagnosed with pneumonia at NYU Langone Hospital-Brooklyn. Without an available COVID-19 test, they sent her home as a suspected case. She was prescribed hydroxychloroquine and azithromycin, which helped improve some symptoms, but not her breathing.
When she was unable to stand, and had severe respiratory problems, her son contacted Dr. Richard Horowitz, a specialist who was treating his sister for Lyme disease, who suggested using glutathione to help reduce the inflammation and protect Bruzzese’s lung tissue. The results were dramatic.
Within one hour after receiving a 2,000 mg dose of glutathione, her breathing was better, and she could stand. She continued to take glutathione for five days and has not had a relapse. Speaking to a reporter from the New York Post, Horowitz shared that he is working to design an extensive clinical trial to prove the effectiveness of what he calls “an easy treatment that is not expensive.”
May 5, 2020, Memorial Sloan Kettering Cancer Center posted a trial to Clinicaltrials.gov announcing a study involving the use of NAC in patients with COVID-19. In this first-of-its-kind research, the study team plans to enroll patients with severe disease: One group in the study will receive 6 grams of NAC intravenously each day in addition to other treatments.
About the same time the study was announced by Memorial Sloan Kettering, a Russian scientist published papers proposing that glutathione plays a crucial role in a person’s ability to respond to a COVID-19 infection and the resulting severity of disease.
Additionally, Dr. Alexey Polonikov, from Kursk State Medical University, theorizes glutathione can be used as a preventive against, and treatment of the illness.